Table 2 Univariate and multivariate analysis for overall survival*.

From: The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization

Variable

Univariate analysis

Multivariate analysis

HR

95% CI

P value

HR

95% CI

P value

Age (y)

1.003

0.986–1.020

0.720

Sex

 Female vs. male

0.920

0.541–1.564

0.758

Etiology

 Hepatitis infection vs. Other

0.749

0.398–1.410

0.370

Child-Pugh class

 B vs. A

0.943

0.490–1.814

0.861

ECOG

 2 vs. 0–1

2.208

1.294–3.180

0.002

1.952

1.239–3.076

0.004

PVTT

 Yes vs. No

1.658

1.124–2.447

0.011

1.398

0.934–2.093

0.103

Extrahepatic spread

 Yes vs. No

1.376

0.938–2.017

0.103

1.214

0.825–1.787

0.324

No. of HCC nodules

 ≥2 + Diffused vs. 1

1.072

0.735–1.565

0.718

   

Baseline AFP (ng/ml)

 ≥200 vs 200

1

0.669–1.494

0.999

AFP change

 Nonresponse vs. response

1.863

1.268–2.738

0.002

1.710

1.147–2.551

0.009

  1. HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PVTT, portal vein tumor thrombosis; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization.
  2. *To avoid effect of colinearity with variables, BCLC and ascites were not included in the model.